DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
1-Year Return
0.48%
This Quarter Return
-10.55%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$353M
AUM Growth
-$40.7M
(-10%)
Cap. Flow
+$5.47M
Cap. Flow
% of AUM
1.55%
Top 10 Holdings %
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$2.91M |
| 2 |
Mineralys Therapeutics
MLYS
|
$2.58M |
| 3 |
Stoke Therapeutics
STOK
|
$1.81M |
| 4 |
Inogen
INGN
|
$1.78M |
| 5 |
Denali Therapeutics
DNLI
|
$1.74M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$3.58M |
| 2 |
Axogen
AXGN
|
$3.07M |
| 3 |
AtriCure
ATRC
|
$1.59M |
| 4 |
Alkermes
ALKS
|
$875K |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$816K |
Sector Composition
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Lineage Cell Therapeutics
LCTX
$279M
| $1.13M | 0.32% |
2,511,374
| – | – |
|
52
Alector
ALEC
$305M
| $1.12M | 0.32% |
912,928
| – | – |
|
53
Foghorn Therapeutics
FHTX
$326M
| $1.11M | 0.32% |
304,752
+118,035
| +63% | +$431K |
|
54
Immatics
IMTX
$761M
| $1.1M | 0.31% |
245,000
| – | – |
|
55
Structure Therapeutics
GPCR
$1.27B
| $1.02M | 0.29% |
59,000
+23,500
| +66% | +$407K |
|
56
VYNE Therapeutics
VYNE
$7.62M
| $1.01M | 0.29% |
+636,103
| New | +$1.01M |
|
57
MediWound
MDWD
$177M
| $1M | 0.28% |
64,479
| – | – |
|
58
Gossamer Bio
GOSS
$668M
| $999K | 0.28% |
907,854
-501,408
| -36% | -$552K |
|
59
BioNTech
BNTX
$27B
| $956K | 0.27% |
10,500
+2,000
| +24% | +$182K |
|
|
AUTL
60
Autolus Therapeutics
AUTL
$389M
| $909K | 0.26% |
586,667
| – | – |
|
|
SAGE
61
DELISTED
Sage Therapeutics
SAGE
| $860K | 0.24% |
108,200
| – | – |
|
62
Korro Bio
KRRO
$312M
| $820K | 0.23% |
+47,086
| New | +$820K |
|
63
Century Therapeutics
IPSC
$43.6M
| $811K | 0.23% |
1,704,232
| – | – |
|
64
Larimar Therapeutics
LRMR
$337M
| $799K | 0.23% |
371,434
| – | – |
|
65
PolyPid
PYPD
$54.8M
| $789K | 0.22% |
291,273
| – | – |
|
66
Taysha Gene Therapies
TSHA
$917M
| $726K | 0.21% |
522,500
| – | – |
|
|
BCYC
67
Bicycle Therapeutics
BCYC
$496M
| $686K | 0.19% |
80,799
-40,000
| -33% | -$340K |
|
68
Neurogene
NGNE
$285M
| $603K | 0.17% |
51,500
| – | – |
|
69
Cardiff Oncology
CRDF
$144M
| $471K | 0.13% |
+150,000
| New | +$471K |
|
70
Erasca
ERAS
$457M
| $466K | 0.13% |
+340,000
| New | +$466K |
|
71
InflaRx
IFRX
$112M
| $459K | 0.13% |
+450,000
| New | +$459K |
|
72
Adicet Bio
ACET
$60M
| $453K | 0.13% |
600,000
| – | – |
|
73
Aquestive Therapeutics
AQST
$656M
| $412K | 0.12% |
142,000
+15,000
| +12% | +$43.5K |
|
74
Compugen
CGEN
$134M
| $398K | 0.11% |
272,402
-174,800
| -39% | -$255K |
|
75
ADC Therapeutics
ADCT
$398M
| $316K | 0.09% |
224,081
| – | – |
|